Background. Nontuberculous mycobacteria (NTM) disease is increasing worldwide and is an important cause of morbidity and mortality. It is found that 20 to 30% of NTM isolates are of extrapulmonary origin. However, Studies about extrapulmonary NTM infections have been limited. Thus, we aim to describe the diversity of NTM infections and correlate these observations with clinical data.
Methods. We analyzed all symptomatic patients with positive NTM cultures in sterile extrapulmonary sites at three tertiary care centers in South Korea between January 2006 and June 2018. We collected patient information including predisposing factors, diversity of NTM isolates, antimicrobial susceptibility testing, treatment regimens, and outcomes.
Results. A total of 117 patients (46 males vs. 71 females) were included. The median age of the patients was 54 years. There are a lot of infections associated with medical procedures like surgery, but about half of cases (54.7%) are unknown origin. Skin and soft-tissue infections predominated (34.2%), followed by bone and joint infections (28.2%). Of 117 NTM isolates, 66 NTM subspecies were identified. Mycobacterium intracellulare (34.8%) was the most common species identified, followed rapid-growing NTM (RGM) species such as M. fortuitum complex (21.2%), M. abscessus (15.2%), M. massiliense (10.6%), and M. chelonae (9.1%). In skin and soft-tissue infections, RGM species were predominantly identified (26/28, 92.9%), whereas slow-growing NTM (SGM) species were mainly identified in bone and joint infections (18/26, 69.2%). The difference of isolated sites was verified by post hoc test and female sex (OR 4.72; P < 0.001) and skin and soft-tissue infections (OR 25.33; P < 0.001) were identified as predictors of RGM by logistic regression analysis. Based on antimicrobial susceptibility testing, fluoroquinolone and macrolide were mainly used for RGM treatment, and rifamycin-ethambutol-macrolide-based regimen was predominantly used for SGM treatment.
Conclusion. Skin and soft-tissue infection were predominantly caused by RGM, whereas bone and joint infection is mainly caused by SGM. Species-specific and region-specific data that integrate clinical and microbiologic information is crucial in determining treatment direction.
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Prognostic Factors for Unfavorable Outcomes of Patients with Spinal Tuberculosis in a Country with an Intermediate Tuberculosis Burden: a Multi-Center Cohort Study
Methods. We performed a multi-center retrospective cohort study of patients with spinal TB. The clinical features, comorbidities, laboratory data, imaging findings and treatment outcomes of the patients were analyzed. The unfavorable outcome was defined according to previous studies. The prognostic factors for unfavorable outcomes as the primary outcome were determined using multivariate logistic regression analysis and a linear mixed model were used to compare time course of inflammatory markers during treatment.
Results. A total of 185 patients (85 males and 100 females) were included. The mean age of the patients was 57.2 years. Of them, 115 underwent surgery during treatment, with a median treatment duration of 12 months. Fifty-nine patients had unfavorable outcomes. In multivariate regression analysis, the factors associated with unfavorable outcome were old age (odds ratio [OR], 2.51; P = 0.034), acid-fast bacilli (AFB) smear positivity in specimens obtained through biopsy (OR, 3.05; P = 0.039), and elevated erythrocyte sedimentation rate (ESR) at the end of treatment (OR, 3.85; P = 0.002). Patients with unfavorable outcomes had a significant trend toward higher ESR during treatment compared with patients with favorable outcome (P = 0.009). Duration of anti-TB and surgical treatment did not affect prognosis.
Conclusion. Elevated ESR at the end of treatment could be used as a marker to identify spinal TB patients with a poor prognosis. Patients whose ESR are not normalized during treatment, as well as those with old age and AFB smear positivity, should be aware of unfavorable outcomes.
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Tele-TB: Using TeleMedicine to Increase Access to Directly Observed Therapy for Latent Tuberculosis Infections

Background.
Otherwise healthy patients with latent tuberculosis infection (LTBI) have a 10 percent lifetime risk of progression to active TB disease. This risk is higher in recently exposed persons, young children, and the immunocompromised. Treatment of LTBI decreases the risk of progression. However, traditional treatment regimens required either daily isoniazid (INH) for 9 months, with historically poor compliance, or 12-week directly-observed therapy (DOT) with INH and rifapentine (RPT), with improved compliance but challenges of coordinating weekly clinic visits, further complicated if patients must travel a great distance for care and/or miss considerable amounts of time from work or school to attend encounters.
Methods. Our referral area is complicated by congested traffic often resulting in one-way commutes in excess of 2 hours. These travel times would be prohibitive for conducting traditional weekly in-clinic DOT. In an effort to improve access to DOT, we implemented TeleMedicine LTBI DOT within a military pediatric infectious diseases clinic. Local providers were requested to refer patients aged two and older diagnosed with LTBI to our DOT TeleMedicine clinic. All patients without absolute contraindications for receiving INH and/or RPT were offered LTBI treatment via weekly TeleMedicine DOT or daily INH. If the family opted for TeleMedicine DOT, the first visit was performed in person to discuss treatment options, demonstrate use of the TeleMedicine software, and to ensure the patient was able to take the medications. Baseline information about patient travel time to our facility for patients enrolled in the LTBI DOT clinic was determined.
Results. To date, seven patients have completed LTBI treatment via TeleMedicine DOT. Average one-way travel time to our facility for patients participating in the TeleMedicine DOT was 72 minutes. Actual time spent in the TeleMedicine DOT encounters was less than 10 minutes. Appointments were arranged to take place outside usual school and work hours so patients could complete DOT with minimal interruptions to daily life, resulting in 100% treatment compliance and completion.
Conclusion. Conducting DOT using TeleMedicine is a viable and time-saving measure that still allows for high levels of patient compliance and treatment completion while minimizing interruptions to academic and work schedules.
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